CMTM6, a potential immunotherapy target
| Autor: | Jie Liang, Bei Zhang, Dongchang Zhai, Shaohua Li, Haining Meng, Wei Rao, Wei Li, Jinzhen Cai, Shuo Xu, Fengqi Zhu, Dan Xu, Mengli Cui |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_treatment Cell Regulator Biology B7-H1 Antigen Neoplasms PD-L1 Tumor Microenvironment medicine Humans MARVEL Domain-Containing Proteins Cell Membrane Cancer Immunosuppression General Medicine Immunotherapy medicine.disease Immune checkpoint Transmembrane protein medicine.anatomical_structure Oncology Cancer research biology.protein Tumor Escape Lysosomes Myelin Proteins |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 148:47-56 |
| ISSN: | 1432-1335 0171-5216 |
| DOI: | 10.1007/s00432-021-03835-9 |
| Popis: | The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6), which binds to the programmed death ligand 1 (PD-L1) and stabilizes the expression of PD-L1 on the cell surface, has been recently discovered as a novel regulator of PD-L1 expression in cancer. PD-L1 is an immune checkpoint inhibitory molecule that can mediate the immune escape of tumor cells in various tumors and has been studied intensively in recent years. In 2017, two articles simultaneously reported that CMTM6 can stabilize the expression of PD-L1 on the plasma membrane and prevent PD-L1 from being degraded by lysosomes; therefore, CMTM6 may play an important role in tumor cell immune escape and immunosuppression. At present, there are few studies on the relationship between the expression of CMTM6 and PD-L1 in different tumors and diseases. These studies together suggested that CMTM6 may be a potential novel immunotherapy target. In this review, we briefly describe the latest research progresses of CMTM6 in various cancers and other diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink